- Home
- HOPE vs XNCR Comparison
HOPE vs XNCR Comparison
Compare HOPE & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | XNCR |
|---|---|---|
| Founded | 1986 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | HOPE | XNCR |
|---|---|---|
| Price | $11.51 | $16.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $13.25 | ★ $22.44 |
| AVG Volume (30 Days) | ★ 1.0M | 738.7K |
| Earning Date | 01-26-2026 | 11-05-2025 |
| Dividend Yield | ★ 4.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $431,631,000.00 | $150,132,000.00 |
| Revenue This Year | $19.31 | $18.81 |
| Revenue Next Year | $12.90 | N/A |
| P/E Ratio | $29.84 | ★ N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $8.83 | $6.92 |
| 52 Week High | $13.50 | $26.59 |
Technical Indicators
Market Signals| Indicator | HOPE | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 69.95 | 54.79 |
| Support Level | $11.40 | $16.44 |
| Resistance Level | $11.66 | $17.62 |
| Average True Range (ATR) | 0.26 | 0.93 |
| MACD | 0.10 | -0.16 |
| Stochastic Oscillator | 88.63 | 36.50 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services and other banking services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.